Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Janssen-Cilag Ltd.
This is an open-label (all people know the identity of the intervention), multi-center (study conducted at multiple sites) study. In this study approximately 209 participants will be observed. Participants receiving topiramate will be observed monthly for 3 months. Safety assessments will include evaluation of adverse events and body weight of the participants which will be monitored throughout the study. The total duration of this study will be approximately 3 months.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants who experiencing migraine three or more times per month and require prophylaxis medication
Participants having at least 6 months of migraine history (diagnosed as per international headache society criteria with or without aura)
Other indications for migraine prophylaxis are: the use of acute treatment medication too frequently (more than 2 treatment days per week); an increasing frequency of headaches that are non-responsive to acute therapy; requiring rescue therapy more than once a month
Participants who are seen to benefit from topiramate based upon the physician's judgment
You may not be if
Headaches other than migraine or episodic tension or sinus headaches or having headaches exceeding 15 days per month
Onset of migraine after age 50
An exclusively migraine aura without headache or a painful condition other than migraine pain
Having significant history of unstable medical disease
At risk in terms of the contraindication in the product insert of topiramate
Clareo Health | A Study of Prophylaxis for Migraine Patients With Topiramate in India
